---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-012530"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:56:56.703282+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine licenses anti-TMPRSS6 antibodies from Mabwell; $10M upfront, up to $412.5M milestones

## Summary
- Exclusive license to MWTX-003 and other anti-TMPRSS6 mAbs for US, Europe, and territories outside Greater China and SE Asia.
- Upfront cash payment of $10M; total potential milestones up to $412.5M; tiered mid-to-high single-digit royalties on net sales.
- MWTX-003 is phase 1-ready with FDA IND accepted; Disc plans to start phase 1 in healthy volunteers in H2 2023.
- Antibodies target TMPRSS6 to modulate iron homeostasis, with potential in beta-thalassemia and polycythemia vera.

## SEC filing metadata
- accession: 0001193125-23-012530
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523012530/0001193125-23-012530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523012530/d447304d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-012530
- JSON: https://secwatch.observer/filing/0001193125-23-012530.json
- Plain text: https://secwatch.observer/filing/0001193125-23-012530.txt

## Key facts
- Material Agreements
  Disc Medicine, Inc. entered into Exclusive License Agreement with Mabwell Therapeutics, Inc. valued at $10 million dollars (effective 2023-01-19).
  - Action: entry
  - Agreement: license
  - Counterparty: Mabwell Therapeutics, Inc.
  - Value: $10 million dollars
  - Effective: 2023-01-19
  source text: On January 19, 2023, Disc Medicine, Inc. (“Disc”) entered into an exclusive license agreement with Mabwell Therapeutics, Inc. (“Mabwell”) (a wholly-owned subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd), pursuant to which Mabwell granted Disc an exclusive and sublicensable license under certain patent rights, know-how, and materials to develop and commercialize antibody products containing Mabwell’s MWTX-001, MWTX-002, and MWTX-003 antibodies, along with limited variants thereof, in all fields of use, in all territories other than Greater China (Mainland China, Hong Kong, Macau and Taiwan) and Southeast Asia (Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, Philippines, Singapore, Thailand and Vietnam).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312523012530/0001193125-23-012530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.